HUMHumana Inc.

Humana Inc. (HUM) | Price: $442.37 | Today's Change: +4.52%

---

What Happened

Humana filed an 8-K with the SEC on 2026-11-09, disclosing its financial results for Q3 FY2026 under Items 8.01 and 9.01. The filing reports revenues of $97.15 billion for the quarter, net income of $1.984 billion, and operating income of $3.512 billion. Diluted earnings per share came in at $16.43, with basic EPS at $16.47 — figures that represent the company's official, XBRL-tagged results for the period.

---

Why It Matters

For investors, the headline numbers signal a meaningful step forward in profitability. A net income figure of nearly $2 billion alongside an operating income of over $3.5 billion suggests that Humana is generating substantial earnings power at the operational level, not just at the top line. The revenue figure of $97.15 billion underscores the sheer scale of the company's insurance and healthcare services operations. The stock's sharp move of +4.52% on the day of this report suggests the market is responding positively to these disclosed results. Notably, shares are trading at $442.37, which is above the $410.00 price target established in StockWatch's existing initiating coverage published on 2026-09-25 — a gap that investors following that prior coverage will want to weigh carefully in light of this new data.

---

Analysis

The Q3 FY2026 results, as filed, paint a picture of a large-scale managed care operator demonstrating operational leverage. Operating income of $3.512 billion against revenues of $97.15 billion implies an operating margin that, while modest in percentage terms given the nature of insurance economics, is meaningful in absolute dollar terms at this revenue scale. The EPS figures — $16.43 diluted and $16.47 basic — are notably close together, suggesting limited dilution from share-based compensation or convertible instruments, which is a broadly constructive technical signal for existing shareholders.

Key items to watch going forward include:

• Medicare Advantage dynamics: Given Humana's heavy exposure to Medicare Advantage, any regulatory or reimbursement updates from CMS for the upcoming plan year will remain a critical variable for profitability.
• Medical loss ratio trends: The filing does not provide explicit MLR data in the structured XBRL facts available here, but that figure will be closely scrutinized by analysts in the full earnings materials accompanying this 8-K.
• Revenue trajectory: Whether $97.15 billion in Q3 revenues reflects membership growth, premium rate increases, or a combination of both is a key distinction that will shape the forward narrative.
• Cost management: Operating income of $3.5B is a strong absolute figure, but sustainability depends on Humana's ability to manage claims costs in a challenging utilization environment.

The stock's move today suggests the market has taken this disclosure positively. Investors should review the full financial exhibits attached to this 8-K filing for the complete picture.

---

Disclaimer

This report is a news and informational analysis based solely on data contained in the referenced SEC filing and its official XBRL-tagged financial facts. It does not constitute investment advice, and no Buy, Hold, or Sell rating or price target is issued or implied herein. Investors should conduct their own due diligence and consult a qualified financial professional before making any investment decisions. Past financial performance is not necessarily indicative of future results.

Existing Coverage

StockWatch has full coverage on HUM, published 2026-09-25. Read our Initiating Coverage →

Source

Filed with the SEC on 2026-11-09. Read the original filing on EDGAR: https://www.sec.gov/Archives/edgar/data/49071/000004907126000068/hum-20261109.htm